ID | 118880 |
著者 |
Takeuchi, Eiji
National Hospital Organization Kochi Hospital
Kondo, Kensuke
Tokushima University
Okano, Yoshio
National Hospital Organization Kochi Hospital
國重, 道大
National Hospital Organization Kochi Hospital
Kondo, Yoshihiro
National Hospital Organization Kochi Hospital
Kadota, Naoki
National Hospital Organization Kochi Hospital
Machida, Hisanori
National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo
National Hospital Organization Kochi Hospital
Naruse, Keishi
National Hospital Organization Kochi Hospital
軒原, 浩
Tokushima University
|
キーワード | Early death
Early mortality factors
Immune checkpoint inhibitors
Lung cancer
Monotherapy
|
資料タイプ |
学術雑誌論文
|
抄録 | Purpose: Immune checkpoint inhibitors (ICI) are a promising treatment, but may cause hyperprogressive disease and early death. The present study investigated early mortality factors in ICI monotherapy for lung cancer.
Patients and methods: We retrospectively reviewed all patients diagnosed with advanced or metastatic non-small cell lung cancer (NSCLC) and treated with ICI monotherapy (nivolumab, pembrolizumab, and atezolizumab) between March 2016 and August 2021 at National Hospital Organization Kochi Hospital and Tokushima University. Early death was defined as patients who died within 60 days of ICI treatment. Results: A total of 166 patients were included. The majority of patients (87%) had an Eastern cooperative oncology group (ECOG) Performance status (PS) of 0/1. There were 21 early deaths. Significant differences were observed in ECOG PS, the histological type, liver metastasis, tumor size, the white blood cell count, neutrophils (%), lymphocytes (%), the neutrophilto-lymphocyte ratio in serum (sNLR), C-reactive protein (CRP), and albumin between the groups with or without early death. Univariate logistic regression analyses identified ECOG PS score ≥ 2, liver metastasis, tumor size ≥ 5 cm, neutrophils ≥ 69%, lymphocytes < 22%, sNLR ≥ 4, CRP ≥ 1 mg/dl, and albumin < 3.58 g/dl as significant risk factors for early death. A multivariate logistic regression analysis revealed that liver metastasis (Odds ratio [OR], 10.3; p = 0.008), ECOG PS score ≥ 2 (OR, 8.0; p = 0.007), and a smoking history (OR, 0.1; p = 0.03) were significant risk factors for early death. Conclusion: Liver metastases, ECOG PS score ≥ 2, and a non-smoking history are early mortality factors in ICI monotherapy for advanced or metastatic NSCLC. |
掲載誌名 |
Journal of Cancer Research and Clinical Oncology
|
ISSN | 14321335
01715216
|
cat書誌ID | AA0025708X
|
出版者 | Springer-Verlag
|
巻 | 149
|
号 | 7
|
開始ページ | 3139
|
終了ページ | 3147
|
発行日 | 2022-07-24
|
権利情報 | This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
|
EDB ID | |
出版社版DOI | |
出版社版URL | |
フルテキストファイル | |
言語 |
eng
|
著者版フラグ |
出版社版
|
部局 |
医学系
病院
|